Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Interest & Investment Income: 2021-2025

Historic Interest & Investment Income for Allogene Therapeutics (ALLO) over the last 5 years, with Sep 2025 value amounting to $3.9 million.

  • Allogene Therapeutics' Interest & Investment Income fell 41.45% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year decrease of 20.24%. This contributed to the annual value of $20.2 million for FY2024, which is 10.08% up from last year.
  • According to the latest figures from Q3 2025, Allogene Therapeutics' Interest & Investment Income is $3.9 million, which was down 36.54% from $6.2 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Interest & Investment Income ranged from a high of $6.7 million in Q3 2024 and a low of $186,000 during Q4 2021.
  • Over the past 3 years, Allogene Therapeutics' median Interest & Investment Income value was $5.4 million (recorded in 2024), while the average stood at $4.9 million.
  • Per our database at Business Quant, Allogene Therapeutics' Interest & Investment Income skyrocketed by 1,382.26% in 2022 and then plummeted by 51.68% in 2024.
  • Over the past 5 years, Allogene Therapeutics' Interest & Investment Income (Quarterly) stood at $186,000 in 2021, then surged by 1,382.26% to $2.8 million in 2022, then spiked by 127.24% to $6.3 million in 2023, then tumbled by 51.68% to $3.0 million in 2024, then slumped by 41.45% to $3.9 million in 2025.
  • Its Interest & Investment Income was $3.9 million in Q3 2025, compared to $6.2 million in Q2 2025 and $5.5 million in Q1 2025.